Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 19/20 | 0.65 |
| ▸ | CHRM1 | P11229 | 19/20 | 0.65 |
| ▸ | CHRM3 | P20309 | 19/20 | 0.65 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.59 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4174447 | 1.00 | CHRM2 (0.65) | CHRM2CHRM1CHRM3KEAP1NFE2L2 | |
| SCHEMBL8362612 | 1.00 | CHRM2 (0.65) | CHRM2CHRM1CHRM3KEAP1NFE2L2 | |
| SCHEMBL27521479 | 1.00 | CHRM2 (0.65) | CHRM2CHRM1CHRM3KEAP1NFE2L2 | |
| SCHEMBL27504209 | 1.00 | CHRM2 (0.65) | CHRM2CHRM1CHRM3KEAP1NFE2L2 | |
| SCHEMBL3042380 | 1.00 | CHRM2 (0.65) | CHRM2CHRM1CHRM3KEAP1NFE2L2 | |
| SCHEMBL2795409 | 1.00 | CHRM2 (0.65) | CHRM2CHRM1CHRM3KEAP1NFE2L2 | |
| Bromide SCHEMBL4533779 | 0.98 | CHRM2 (0.64) | CHRM2CHRM1CHRM3KEAP1NFE2L2 | |
| Hydrochloric Acid SCHEMBL4520885 | 0.98 | CHRM2 (0.64) | CHRM2CHRM1CHRM3KEAP1NFE2L2 | |
| Phosphoric Acid SCHEMBL4521257 | 0.94 | CHRM2 (0.60) | CHRM2CHRM1CHRM3KEAP1NFE2L2 | |
| Fumaric Acid SCHEMBL4560208 | 0.93 | CHRM2 (0.59) | CHRM2CHRM1CHRM3KEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056496-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2010-03-04 | — | — | US | claimed |
| US-20100056496-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2010-03-04 | — | — | US | disclosed |
| EP-2059505-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2009-05-20 | — | — | EP | disclosed |
| US-20090105221-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-04-23 | — | — | US | disclosed |
| WO-2008029349-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2008-03-13 | — | — | WO | disclosed |
| EP-1797040-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2007-06-20 | — | — | EP | disclosed |
| EP-1551803-B1 | AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LAB LTD (IN) | 2006-10-11 | — | — | EP | disclosed |
| WO-2006035303-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-04-06 | — | — | WO | disclosed |
| US-5948792-A | POTENT AND SELECTIVE ANTAGONISTS FOR MUSCARINIC M.SUB.3 RECEPTORS WITH LITTLE SIDE EFFECTS. | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056496-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM2 | CHRM2 3/4885CHRM1 4/4885CHRM3 1/4885 |
| US-20090105221-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM2 | CHRM2 3/4885CHRM1 4/4885CHRM3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.